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Abstract
Rationale Lysergic acid diethylamide (LSD) and other sero-
tonergic hallucinogens can induce profound alterations of
consciousness and mystical-type experiences, with reportedly
long-lasting effects on subjective well-being and personality.
Methods We investigated the lasting effects of a single dose of
LSD (200 μg) that was administered in a laboratory setting in
16 healthy participants. The following outcome measures
were assessed before and 1 and 12 months after LSD admin-
istration: Persisting Effects Questionnaire (PEQ), Mysticism
Scale (MS), Death Transcendence Scale (DTS), NEO-Five
Factor Inventory (NEO-FFI), and State-Trait Anxiety
Inventory (STAI).
Results On the PEQ, positive attitudes about life and/or self,
positive mood changes, altruistic/positive social effects, posi-
tive behavioral changes, and well-being/life satisfaction sig-
nificantly increased at 1 and 12 months and were subjectively
attributed by the subjects to the LSD experience. Five-
Dimensions of Altered States of Consciousness (5D-ASC)
total scores, reflecting acutely induced alterations in con-
sciousness, and Mystical Experience Questionnaire
(MEQ30) total scores correlated with changes in well-being/
life satisfaction 12 months after LSD administration. No
changes in negative attitudes, negative mood, antisocial/
negative social effects, or negative behavior were attributed
to the LSD experience. After 12 months, 10 of 14 participants
rated their LSD experience as among the top 10 most mean-
ingful experiences in their lives. Five participants rated the
LSD experience among the five most spiritually meaningful
experiences in their lives. On the MS and DTS, ratings of
mystical experiences significantly increased 1 and 12 months
after LSD administration compared with the pre-LSD screen-
ing. No relevant changes in personality measures were found.
Conclusions In healthy research subjects, the administration
of a single dose of LSD (200 μg) in a safe setting was subjec-
tively considered a personally meaningful experience that had
long-lasting subjective positive effects.
Trial registration Registration identification number:
NCT01878942.
Keywords LSD .Mystical experience . Personality .
Hallucinogen . Humans
Introduction
Classic hallucinogens, including D-lysergic acid diethylamide
(LSD), psilocybin, and dimethyltryptamine (which is
contained in ayahuasca), produce their psychotropic effects
by acting on serotonin 5-hydroxytryptamine-2A (5-HT2A) re-
ceptors (Preller et al. 2017; Rickli et al. 2016). These seroto-
nergic hallucinogens are used for recreational, personal/spiri-
tual, and therapeutic purposes (Nichols 2016). Approximately
10% of US residents reported having used LSD at least once
(Johnston et al. 2016; Krebs and Johansen 2013).
The use of LSD as an adjunct to psychotherapy has been
associated with positive health outcomes in patients with
anxiety that was caused by life-threatening diseases
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(Gasser et al. 2014, 2015; Pahnke et al. 1970), depression
(Rucker et al. 2016), and substance use disorder (Krebs
and Johansen 2012; Savage and McCabe 1973) .
Additionally, self-reports indicated positive lasting effects
on values, attitudes, personality, and well-being that were
attributed to LSD administration (200 μg p.o.) in 24
psychiatrically healthy subjects (McGlothlin et al. 1967).
However, more recent data on similar long-term effects of
experimentally administered LSD in normal subjects are
lacking.
Clinical research on LSD has only very recently been
restarted after no clinical studies were conducted for
40 years (Liechti 2017). With the exception of one clinical
therapeutic trial (Gasser et al. 2014), all recent research on
LSD had an experimental focus on aspects of the acute
effects of LSD in healthy participants (Carhart-Harris
et al. 2016a, b; Dolder et al. 2016; Liechti 2017; Liechti
et al. 2017; Mueller et al. 2017; Preller et al. 2017; Schmid
et al. 2015). Only one recent study investigated lasting
effects and reported increases in trait optimism and open-
ness 2 weeks after LSD (75 μg i.v.) administration in 20
healthy subjects (Carhart-Harris et al. 2016a). In contrast to
LSD, considerably more recent research has been conduct-
ed on psilocybin using doses up to 0.43 mg/kg p.o., includ-
ing reports of positive long-term effects in a total of 129
healthy subjects (Griffiths et al. 2006, 2008, 2011, 2017;
MacLean et al. 2011) and a total of 105 patients
(Bogenschutz et al. 2015; Griffiths et al. 2016; Johnson
et al. 2016; Ross et al. 2016). Psilocybin has been shown
to induce persisting positive changes in attitudes, social
effects, mood, life satisfaction, behavior, and trait openness
in healthy volunteers up to 14 months after administration
(Griffiths et al. 2006, 2008, 2011, 2017; MacLean et al.
2011). Lasting positive effects of hallucinogens have been
linked to their ability to acutely induce profound insights
and mystical-type experiences (Pahnke 1969). Such acute
mystical-type effects of psilocybin have now been charac-
terized in more recent studies including also validated
scales such as the Mystical Experience Questionnaire
(MEQ; Barrett et al. 2015) and Mysticism Scale (MS;
Hood et al. 2001; Hood 1975) in healthy participants
(Barrett and Griffiths 2017; Barrett et al. 2015; Garcia-
Romeu et al. 2015; Griffiths et al. 2006, 2008, 2011,
2017; MacLean et al. 2011). Additionally, these effects
have been correlated with lasting changes after psilocybin
administration (Barrett et al. 2015; Griffiths et al. 2008,
2017; MacLean et al. 2011).
The goal of the present study was to describe the
persisting effects of LSD 1 and 12 months after adminis-
tration of a single dose (200 μg p.o.) in 16 healthy par-
ticipants using psychometric instruments that were not
validated in German but that were similar to those used
in studies of psilocybin (Griffiths et al. 2006, 2008, 2011,
2017). Based on previous research on psilocybin, the first
a priori study hypothesis was that the LSD experience
would be self-rated by the participants on the Persisting
Effects Questionnaire (PEQ) as personally meaningful,
spiritually significant, and positively influencing their
sense of well-being up to 12 months, similar to reports
for psilocybin (Griffiths et al. 2006, 2008, 2011, 2017).
We also hypothesized that LSD would increase total rat-
ings of mystical experiences on the Mysticism Scale (MS;
lifetime version) and total ratings on the Death
Transcendence Scale (DTS) 1 and 12 months after admin-
istration compared with pre-LSD screening (Griffiths
et al. 2006, 2011). We further expected that the acute
alterations in consciousness (Five Dimensions of Altered
States of Consciousness [5D-ASC] total score) and
mystical-type experiences (MEQ30 total score and MS
total score) that are induced by LSD would correlate with
its persisting effects (PEQ, MS total score, and DTS total
score; Griffiths et al. 2008; Griffiths et al. 2017). Finally,
we hypothesized that LSD would produce lasting in-
creases in personality trait openness, similar to the effects
of psilocybin (MacLean et al. 2011).
Methods
Study design
The present study included a priori-planned short-term
(1 month) and long-term (12 months) follow-ups after
the administration of a single dose of LSD and placebo
using a randomized, double-blind, cross-over study with
two experimental test sessions in balanced order. The
washout periods between study sessions were at least
7 days. The study was conducted in accordance with the
Declaration of Helsinki and International Conference on
Harmonization Guidelines in Good Clinical Practice
(ICH-GCP) and approved by the Ethics Committee of
the Canton of Basel, Switzerland, and the Swiss Agency
for Therapeutic Products (Swissmedic). The administra-
tion of LSD in healthy subjects was authorized by the
Swiss Federal Office for Public Health, Bern. The study
was registered at ClinicalTrials.gov (NCT01878942). All
of the subjects provided written informed consent and
were paid for their participation. The present clinical
study also assessed addit ional acute subjective,
autonomic, adverse, endocrine, and pharmacokinetic
effects of LSD as reported in detail elsewhere (Dolder
et al. 2015, 2016, 2017; Liechti et al. 2017; Schmid
et al. 2015; Strajhar et al. 2016). In the present paper,
we report the short- and long-term follow-up safety data
and the sustained effects of LSD.
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Participants
Sixteen healthy subjects (eight men and eight women; mean
age ± SD 28.6 ± 6.2 years; range 25–51 years) were recruited
by word of mouth or an advertisement that was placed on the
web market platform of the University of Basel. All of the
subjects were well-educated. Ten participants had at least a
masters degree, and four were graduate students. The exclu-
sion criteria were age < 25 years or > 65 years, pregnancy,
personal or first-degree relative history of psychotic or major
affective disorder, chronic or acute illness, and illicit drug use
within the last 2 months or during the study period. Seven
subjects had used a hallucinogen one to three times. Nine
subjects were hallucinogen-naive. The exclusion criteria and
drug use histories are reported in detail elsewhere (Schmid
et al. 2015). Additionally, we considered the safety recom-
mendations for high-dose hallucinogen research (Johnson
et al. 2008).
Study procedures
The study included a 1–2 h screening visit with the study
physician, a separate 1 h psychiatric interview, two 25 h test
sessions, a 1-h follow-up visit approximately 1 month
(mean ± SD 37 ± 14 days) after the LSD test session, and a
follow-up mail contact that was scheduled at least 12 months
(491 ± 199 days) after LSD administration. The two test ses-
sions included the administration of either LSD or placebo.
The sessions lasted 25 h each and were conducted in a calm
and neutral hospital research ward environment. The test ses-
sions began at 8:15 a.m. LSD (200 μg) or placebo was admin-
istered at 9:00 a.m. The subjects were under constant supervi-
sion by the study physician until the drug effects ceased up to
16 h after drug administration (1:00 a.m.). Thus, the subjects
were never alone during the first 16 h after drug administra-
tion, and the investigator was in a room next to the subject
during the night up to 24 h. The participants were resting in
hospital beds. They could interact with the investigator, rest,
or listen to music via headphones up to 1:00 a.m., but no
further entertainment was provided and the night was spent
sleeping (1:00 a.m.–08:00 a.m.). The first follow-up was
scheduled approximately 1 month after the LSD session as a
hospital visit. The participants completed questionnaires that
assessed lasting effects (see the BOutcome measures^ section
below) and were asked about adverse events, and a physical
examination was performed. The participants were asked to
report any psychological problems, including depressed
mood, sleeping problems, somatic disorders, and any percep-
tual changes/disorders (e.g., flashbacks). The subjects were
contacted again by regular mail or/and e-mail and asked to
complete the same questionnaires at least 12 months after
the LSD session.
Drugs
LSD was administered in a single oral dose of 200 μg (D-
lysergic acid diethylamide base; Lipomed AG, Arlesheim,
Switzerland). The same dose and gelatin capsule formulation
was used in LSD-assisted psychotherapy in a clinical study
(Gasser et al. 2014). The dose was within the range of doses
that are taken for recreational purposes and expected to induce
robust effects in humans (Passie et al. 2008).
Outcome measures
The present LSD study used the same acute and long-term
outcome measures as the previous psilocybin studies, includ-
ing the PEQ, MS, DTS, and similar and additional personality
measures (Griffiths et al. 2006, 2008, 2011; MacLean et al.
2011). The PEQ, MS, and DTS were unavailable in validated
German versions. Therefore, the original English question-
naires (Griffiths et al. 2006, 2008, 2011) were independently
forward-translated into German by two translators with
German as their mother tongue. Discrepancies between the
two forward-translated versions and other previous German
versions were then discussed, and selected items were
backtranslated. The versions were then pretested for compre-
hension by people with prior LSD use. The non-validated
German versions that were finally used in the study are avail-
able online (Supplementary Appendices 1–3).
Persisting Effects Questionnaire The 143-item PEQ is a
non-validated questionnaire that has previously been used
to study long-term effects of psilocybin (Griffiths et al.
2006, 2008, 2011). A non-validated German version was
used (Supplementary Appendix 1). A total of 140 items are
rated on six-point Likert scales to assess possible changes
in positive or negative attitudes about life and/or self (17
items each), positive and negative mood changes (4 items
each), altruistic/positive and antisocial/negative social
effects (8 items each), and positive and negative behavioral
changes (1 item each; Griffiths et al. 2006). All ratings
reflect persisting changes that are subjectively related to
the LSD experience, and no change would be reflected
by a score of 0. Three additional questions were included
as previously described (Griffiths et al. 2006, 2011): (1)
How personally meaningful was the experience? (1 = no
more than routine, everyday experiences; 2 = similar to
meaningful experiences that occur on average once or
more per week; 3 = similar to meaningful experiences that
occur on average once per month; 4 = similar to meaning-
ful experiences that occur on average once per year;
5 = similar to meaningful experiences that occur on aver-
age once every 5 years; 6 = among the 10 most meaningful
experiences of my life; 7 = among the 5 most meaningful
experiences of my life; 8 = the single most meaningful
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experience of my life); (2) indicate the degree to which the
experience was spiritually significant for you (1 = not at
all; 2 = slightly; 3 = moderately; 4 = very much; 5 = among
the 5 most spiritually significant experiences of my life;
6 = the single most spiritually significant experience of
my life); and (3) do you believe that the experience and
your contemplation of the experience have led to a change
in your current sense of personal well-being or life satis-
faction? (+ 3 = increased very much to − 3 = decreased
very much; 0 indicates no change; Griffiths et al. 2006,
2008, 2011). The questionnaires were completed 1 and
12 months after LSD administration. One subject was lost
to follow-up at 12 months, one subject did not complete all
of the questions at 1 and 12 months, and one subject did
not complete all of the questions at 1 month, thus resulting
in data from 14 subjects at both time points.
Mysticism Scale TheMS is a validated 32-item questionnaire
that was developed to assess primary mystical experiences
(Hood et al. 2001; Hood 1975). The MS has previously been
used to measure mystical experiences that were induced by
psilocybin (Griffiths et al. 2006, 2008, 2011; MacLean et al.
2011). A non-validated German version was used
(Supplementary Appendix 2). The items were rated on a
nine-point Likert scale (− 4 = this description is extremely
not true of my own experience or experiences to + 4 = this
description is extremely true of my own experience or expe-
riences). The scale consists of 16 positively worded state-
ments and 16 negatively worded statements. Negative items
were reverse scored and summed with the positive items. A
total score and three empirically derived factors were calcu-
lated as previously described: interpretation (corresponding to
noetic quality, sacredness, and deeply felt positive mood),
introvertive mysticism (corresponding to internal unity, tran-
scendence of time and space, and ineffability), and
extrovertive mysticism (corresponding to unity of all things/
all things are alive; Griffiths et al. 2006). The MS was com-
pleted 24 h after the administration of LSD and placebo, and
the participants were asked to retrospectively rate their expe-
riences relative to their experiences since receiving the drug
that morning. For the lifetime version, the participants were
instructed to answer the questions relative to their total life
experiences. The lifetime version was used at screening and
1 and 12 months after LSD administration. One subject was
lost to follow-up at 12 months, and one subject did not com-
plete all of the questions at 12 months, thus resulting in com-
plete datasets for 14 subjects.
Death Transcendence Scale The validated 26-item DTS in-
cludes five factors/subscales (mysticism, religion, nature, cre-
ativity, and biosocial) reflecting different aspects of death tran-
scendence (Hood and Morris 1983; VandeCreek 1999;
VandeCreek and Nye 1993). A non-validated German version
(Supplementary Appendix 3) was administered at screening
and 1 and 12 months after LSD administration. The items
were rated on a sevent-point scale. One subject was lost to
follow-up at 12 months, and one subject did not complete all
of the questions at 12 months, thus resulting in 14 complete
datasets.
Personality measures The 60-item NEO-Five-Factor
Inventory (NEO-FFI; Borkenau and Ostendorf 2008) was de-
rived from the NEO Personality Inventory (Costa andMcCrae
1995) and used to assess personality traits. The Spielberger
State-Trait Anxiety Inventory (STAI; Form X2) was used to
assess trait anxiety (Spielberger et al. 1970). Measures were
taken at screening and 1 and 12 months after LSD adminis-
tration. One subject was lost to follow-up at 12 months, thus
resulting in 15 complete datasets.
Additional measures of acute mystical-type and mind-
altering effects of LSD Two of the previously described mea-
sures of the acute mystical-type and mind-altering effects of
LSD (Liechti et al. 2017) were again used in the present data
analysis to assess whether the acute response to LSD on these
scales predicted its long-term effects in the follow-up ques-
tionnaires as similarly evaluated for psilocybin in healthy sub-
jects and using the same psychometric scales (Griffiths et al.
2008, 2011, 2017; MacLean et al. 2011). These two measures
were the MEQ (Barrett et al. 2015; Griffiths et al. 2006;
MacLean et al. 2012) and the 5D-ASC (Studerus et al.
2010). A German version (Liechti et al. 2017) of the 43-item
MEQ (Griffiths et al. 2006; MacLean et al. 2012; Pahnke
1969) was used, including six subscales (internal unity, exter-
nal unity, sacredness, noetic quality, deeply felt positivemood,
transcendence of time/space, and ineffability). We also de-
rived the four scale scores of the newly validated revised 30-
item MEQ (mystical, positive mood, transcendence of time
and space, and ineffability; Barrett et al. 2015). The 5D-
ASC was used to assess the peak alterations of consciousness.
The 5D-ASC contains 94 items (visual analog scales; Dittrich
1998; Studerus et al. 2010). The instrument consists of five
subscales/dimensions (Dittrich 1998). The 5D-ASC dimen-
sion BOceanic Boundlessness^ (OB, 27 items) measures de-
realization and depersonalization associated with positive
emotional states, ranging from heightened mood to euphoric
exaltation. The dimension BAnxious Ego Dissolution^ (AED,
21 items) summarizes ego-disintegration and loss of self-
control phenomena associated with anxiety. The dimension
BVisionary Restructuralization^ (VR, 18 items) describes per-
ceptual changes including complex imagery, elementary im-
agery, audio-visual synesthesia, and changed meaning of per-
cepts. Two additional dimensions describe BAuditory
Alterations^ (AA, 15 items) and BReduction of Vigilance^
(12 items). The total 5D-ASC score is the total of all
dimensions.
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The MEQ and 5D-ASC were administered 24 h after drug
administration, and the participants were asked to retrospec-
tively rate drug effects during peak drug effects. Greater acute
effects of psilocybin on the MEQ43 and 5D-ASC predicted
lasting changes in openness in a previous study (MacLean
et al. 2011), and greater acute MEQ30 ratings also predicted
greater changes in well-being/life satisfaction at 6 months in
another study (Griffiths et al. 2017).
Statistical analysis
The data were analyzed using Statistica 12 (StatSoft, Tulsa,
OK, USA). Paired t tests (two-tailed) were used to test for
differences between the acute effects of LSD and placebo on
the MS. Repeated-measures analysis of variance (ANOVA),
with time (screening, 1 month after LSD, and 12 months after
LSD) as the within-subject factor, followed by the Tukey post
hoc test was used to analyze differences between screening
and the two follow-up assessments over time. Sex differences
were assessed by adding sex as a between-subjects factor to
the ANOVA. Persisting effect ratings on the PEQ at 1 or
12 months were compared with 0 (i.e., no change compared
with everyday life) using one-sample t tests because the PEQ
ratings would be attributed to the LSD experience compared
with no change, and there was no measurement at screening.
Associations between the acute response to LSD and main 12-
month outcome measures were assessed using Spearman rank
order correlations. The criterion for significance was P < 0.05.
The values are shown without correction for multiple compar-
isons because of the use of defined a priori hypotheses for
most of the study outcomes.
Results
Acute effects of LSD on the Mysticism Scale
LSD increased the total score and all three factors of the MS
compared with placebo. The total score (mean ± SEM) was
194 ± 14 and 45 ± 9 for LSD and placebo, respectively
(t13 = 8.9, P < 0.001). Ratings of Binterpretation^ were
72 ± 6 and 17 ± 3 after the administration of LSD and placebo,
respectively (t13 = 7.6, P < 0.001). Ratings of Bintrovertive^
were 55 ± 3 and 12 ± 2 after LSD and placebo administration,
respectively (t13 = 13.2, P < 0.001). Ratings of Bextrovertive^
were 67 ± 7 and 16 ± 3 after LSD and placebo administration,
respectively (t13 = 7.0, P < 0.001). The acute effects of LSD
and placebo on the 5D-ASC and MEQ have previously been
reported and are summarized in Table S1 (Liechti et al. 2017).
Acute administration of LSD significantly increased the total
5D-ASC and MEQ30 scores and ratings on all subscales ex-
cept anxiety on the 5D-ASC (Table S1).
Lasting effects of LSD
Persisting Effects Questionnaire Ratings of positive atti-
tudes about life and/or self, positive mood changes,
altruistic/positive social effects, and positive behavioral
changes significantly increased at the 1- and 12-month fol-
low-ups compared with the assumption of no change (rat-
ing = 0; Table 1). Ratings of negative attitudes about life
and/or self, negative mood changes, antisocial/negative social
effects, or negative behavior changes attributed to the LSD
experience (Table 1) were not different at the 1 and 12 month
follow-ups compared with the assumption of no change
(rating 0; Table 1). Ratings of meaningfulness of the LSD
experience (BHow personally meaningful was the LSD
experience^) significantly increased at 1 and 12 months com-
pared with the assumption that the experience would be as
meaningful as an everyday experience (rating = 1; Table 1).
After 12 months, 10 of 14 participants rated the LSD experi-
ence among the top 10 most meaningful experiences in their
lives (rating ≥ 6). Among these 10 participants, five rated it
among the top five most meaningful experiences (rating = 7).
Ratings of spiritual significance (BIndicate the degree to which
the experience was spiritually significant to you^) increased at
both 1 and 12 months compared with the assumption that the
experience would have no spiritual meaning (rating = 1;
Table 1). At 12 months, eight of 14 participants rated the
experience as very strongly spiritual (rating ≥ 4). Among these
eight participants, five reported that the LSD experience was
among the five most spiritually meaningful experiences in
their lives (rating ≥ 5). One of these participants considered
the LSD experience the most spiritually significant experience
in his life (rating = 6). Ratings of well-being or life satisfaction
also significantly increased compared with the assumption of
no change (rating = 0; Table 1). No significant differences in
these three ratings were found between the 1- and 12-month
follow-ups. No subject rated the LSD experience as decreas-
ing well-being or life satisfaction.
Mysticism Scale, lifetime version The MS total score and
introvertive and extrovertive mysticism factor scores signifi-
cantly increased at 1 and 12 months compared with pre-LSD
screening (Table 1). No sex differences were observed.
Death Transcendence Scale The DTS total score and mysti-
cism subscale score significantly increased at 1 and 12months
compared with pre-LSD screening (Table 1). Mysticism rat-
ings significantly increased after 12 months compared with
1 month. No sex differences were observed.
Personality measures On the NEO-FFI, ratings of conscien-
tiousness significantly increased at 12 months compared with
pre-LSD screening (Table 1). No sex differences were ob-
served. No differences in ratings of the other NEO-FFI factors
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were observed over time. On the STAI, no changes in trait
scores were observed over time (Table 1).
Correlations between acute and long-term effects of LSD
Ratings of the acute effects of LSD on the MS, MEQ, and
particularly 5D-ASC total score were positively associated
with several long-term changes that were subjectively attrib-
uted to the LSD experience, which were assessed with the
PEQ, MS, and DTS 12 months after LSD administration
(Table 2). The overall acute mind-altering effects of LSD,
reflected by the 5D-ASC total score, correlated with ratings
of positive changes in mood (Rs = 0.56, P < 0.05), behavior
(Rs = 0.53, P < 0.05), and well-being/life satisfaction
(Rs = 0.53, P < 0.05) on the PEQ and changes in the MS total
score (Rs = 0.62, P < 0.05) and DTS total score (Rs = 0.76,
P < 0.01) at 12months. Associations between the acute effects
of LSD on ratings on the subscales of the 5D-ASC scale and
the long-term effects of LSD are shown in Supplementary
Table 1 Participant ratings (mean [SEM]) and statistics
Screening 1 month 12 months
Persisting Effects Questionnairea T13 P= T13 P=
Positive attitudes about life and/or self 35.1 (5.9) 6.23 *** 39.3 (6.5) 6.24 ***
Positive mood changes 21.8 (5.0) 4.52 *** 32.5 (8.2) 4.11 **
Altruistic/positive social effects 23.2 (5.9) 4.11 ** 28.4 (6.3) 4.72 ***
Positive behavior changes 30.0 (7.1) 4.36 *** 30.0 (7.8) 4 **
Negative attitudes about life and/or self 1.1 (0.6) 1.82 NS 0.5 (0.3) 2.12 NS
Negative mood changes 1.1 (1.1) 1 NS 0.7 (0.7) 1 NS
Antisocial/negative social effects 1.0 (0.9) 1.63 NS 1.8 (1.0) 1.85 NS
Negative behavior changes 0.0 (0.0) 1 NS 0.0 (0.0) 1 NS
T13 P= T13 P=
How personally meaningful was the experience? (score range 1–8)b 5.4 (0.3) 14.17 *** 5.7 (0.4) 11.8 ***
How spiritually significant was the experience? (score range 1–6)b 2.9 (0.5) 4.28 *** 3.4 (0.5) 4.84 ***
Did the experience change your sense of well-being or life
satisfaction? (score range − 3 to + 3, 0 = no change)b
1.0 (0.3) 3.8 ** 1.4 (0.3) 4.76 ***
Mysticism Scaleb F2,26 P=
Interpretation (max score = 108) 65.1 (3.8) 75.9 (5.1) 76.6 (5.5) 3.32 NS
Introvertive (max score = 108) 37.9 (3.7) 52.1 (3.6) ** 52.0 (3.9) ** 8.13 < 0.01
Extrovertive (max score = 172) 47.4 (5.4) 69.5 (8.0) ** 74.4 (6.7) *** 10.43 < 0.001
Total (max score = 288) 151 (10.9) 198 (14.3) ** 203 (14.6) *** 11.13 < 0.001
Death Transcendence Scaleb F2,26 P=
Mysticism (max score = 35) 13.1 (2.0) 21.1 (2.7) ** 24.6 (2.6) ***,# 13.57 < 0.001
Religious (max score = 35) 14.6 (2.1) 16.8 (2.2) 16.6 (2.2) 1.86 NS
Nature (max score = 35) 26.7 (1.0) 27.9 (1.1) 28.4 (1.1) 2.15 NS
Creative (max score = 35) 16.5 (2.2) 15.8 (2.3) 18.2 (2.3) 3.32 NS
Biosocial (max score = 42) 29.1 (1.9) 29.3 (2.1) 28.1 (2.3) 0.96 NS
Total (max score = 182) 101 (4.6) 111 (5.4) * 116 (6.1) ** 7.91 < 0.01
NEO Five-Factor Inventory (NEO-FFI)c F2,28 P=
Neuroticism (max score = 48) 14.4 (2.0) 14.6 (1.5) 13.3 (1.5) 0.41 NS
Extraversion (max score = 48) 30.2 (1.4) 30.5 (2.0) 30. (2.0) 0.20 NS
Openness (max score = 48) 33.4 (2.2) 33.7 (2.3) 33.0 (2.5) 0.16 NS
Agreeableness (max score = 48) 33.1 (1.5) 32.6 (1.7) 33.8 (1.6) 1.09 NS
Conscientiousness (max score = 48) 30.1 (2.2) 31.8 (2.1) 34.8 (2.3) * 4.48 < 0.05
State-Trait Anxiety Inventory (STAI)c F2,28 P=
Trait score (max score = 80) 33.1 (2.3) 31.0 (1.8) 32.4 (1.8) 1.13 NS
NS not significant
a Data are expressed as percentage of maximum possible score. N = 14 subjects
bN = 14 subjects
cN = 15 subjects
*P < 0.05; **P < 0.01; ***P < 0.001, post hoc comparison with screening; #P < 0.05 compared with 1 month
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Table S2 and were consistent with those using the total 5D-
ASC score.
Acute mystical-type effects, reflected by the MEQ30 total
score, correlated with PEQ well-being/life satisfaction ratings
at 12 months (Rs = 0.60, P < 0.05). The extent of acute
mystical-type experiences, reflected by the MS total score
and MEQ30 total score, also correlated with changes in DTS
total scores at 12 months (Rs = 0.66, P < 0.01, and Rs = 0.65,
P < 0.05, respectively).
Transient and lasting adverse effectsAt the 1-month follow-
up, one subject reported problems falling asleep and having
more vivid dreams over 10 days after LSD administration.
None of the participants reported any psychological problems
or perceptual changes/disorders (e.g., flashbacks) up to
1 month after the LSD session. There were no spontaneous
reports of adverse effects at the 12-month follow-up.
Discussion
The main findings of the present study were that the adminis-
tration of a single dose of LSD (200 μg p.o.) in healthy vol-
unteers induced a subjectively meaningful experience with
lasting positive effects that were attributed to the LSD expe-
rience by the participants. Greater ratings of acute LSD-
induced alterations of mind on the 5D-ASC and/or mystical-
type experiences on the MEQ30 scales were associated with
greater ratings of well-being 12 months after the experience
and changes in lifetime mystical experiences. LSD did not
increase trait openness or produce relevant changes in person-
ality measures. In the present study, LSD was not associated
with lasting negative effects, as no lasting increases of nega-
tive attitudes, negative mood, and negative behavior could be
observed after one and 12 months.
The present findings confirmed most of our hypotheses
and complemented similar recent reports of lasting effects
of psilocybin in healthy subjects using the same outcome
measures (Griffiths et al. 2006, 2008, 2011, 2017;
MacLean et al. 2011). The lasting effects of LSD were
also reported in psychiatrically healthy subjects in older
studies (McGlothlin et al. 1967). Short-term effects on
personality measures were reported in one recent study
(Carhart-Harris et al. 2016a). Specifically, in the older
study by McGlothlin et al. (1967), psychological tests
were administered before and 2 weeks and 6 months after
three single dose sessions (200 μg LSD p.o. in each ses-
sion) in 24 healthy subjects to explore potential changes
in attitudes and values (McGlothlin et al. 1967). The par-
ticipants were graduate students, were paid for participa-
tion, were LSD-naive, and received the drug in a secure
setting but without suggestions of possible lasting effects
(McGlothlin et al. 1967). In contrast to our study, the drug
sessions were held in a Btastefully decorated room specif-
ically designed to enhance the drug experience^ without
distractions by experiments (McGlothlin et al. 1967). A
higher proportion of participants reported lasting effects
on personality and greater appreciation of music and art
Table 2 Correlations between
the acute and long term effects of
LSD
Acute LSD effect
total MS score total MEQ30 score total 5D-ASC
score
Long term LSD effect
Persisting effects questionnaire (PE)
Positive attitudes about life and/or self 0.30 0.50 0.48
Positive mood changes 0.33 0.51 0.56
Altruistic/positive social effects 0.04 0.25 0.27
Positive behavior changes 0.45 0.25 0.53
Personal meaning of experience 0.09 0.22 0.48
Spiritually significance of experience 0.41 0.29 0.52
Change in well-being/life satisfaction 0.51 0.60 0.53
Mysticism Scale (MS), lifetime
Change in total MS score 0.38 0.36 0.62
Death Transcendence Scale (DTS)
Change in total DTS score 0.66 0.65 0.76
Values are Spearman rank coefficients. Significant correlations are marked in bold (P < 0.05) or bold and italic
(P < 0.01) font
MS Mysticism Scale, lifetime version, MEQ30 30-item Mystical Experience Questionnaire, 5D-ASC Five
Dimensions of Altered States of Consciousness Scale
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6 months after LSD administration compared with con-
trols who received either amphetamine (20 mg p.o.) or a
very low dose of LSD (25 μg p.o.; McGlothlin et al.
1967). The majority of the participants also rated the
acute LSD response as a very dramatic and interesting
experience. However, the pre-LSD vs. post-LSD compar-
ison of a series of personality and creativity test ratings
did not document relevant changes (McGlothlin et al.
1967). These previous findings of LSD-attributed subjec-
tive changes in attitudes, values, and esthetic interests in
the absence of alterations in more objective test measures
(McGlothlin et al. 1967) were largely confirmed by the
present results.
More recently, Griffiths and colleagues administered a sin-
gle dose of psilocybin in a supportive setting in 30
hallucinogen-naive and spiritually active healthy subjects to
evaluate the long-term effects of psilocybin (Griffiths et al.
2006, 2008). A cross-over study design was used, including
a control condition (methylphenidate, 40 mg/70 kg p.o.), to
assess the acute effects of psilocybin (30 mg/70 kg p.o.). The
MS and MEQ were used to assess acute mystical-type expe-
riences (Barrett et al. 2015; Griffiths et al. 2006), similar to the
present study (Liechti et al. 2017). Lasting effects of psilocy-
bin were assessed at 2 and 14 months using the PEQ and MS
(Griffiths et al. 2008). In contrast to the present study with
LSD, the volunteers did not receive monetary compensation
for participation. The investigators met with the participants
on four occasions (for a total of 8 h) before the psilocybin
session to prepare them for the experience. In contrast to the
present study, this presession preparation explicitly included
the monitor’s expectation that the psilocybin session could
increase personal awareness and insight (Griffiths et al.
2006) and thus could have lasting positive effects.
Additionally, all of the subjects participated at least intermit-
tently in religious or spiritual activities, in which 56% of the
volunteers reporting daily engagement, and 39% indicated at
least monthly activities (Griffiths et al. 2006, 2008). Griffiths
and colleagues also conducted a dose-effect study that includ-
ed the administration of four different single doses of psilocy-
bin and placebo in 18 participants and assessed lasting effects
at 1 and 14 months using the PEQ, MS, DTS, and NEO
Personality Inventory (NEO-PI) (Griffiths et al. 2011), similar
to the present study. Similar to LSD in the present study, a
single dose of psilocybin (30 mg/70 kg) significantly in-
creased ratings of acute mystical-type experiences on the
MS and MEQ (Barrett et al. 2015; Griffiths et al. 2006,
2011). However, 17 of the overall 54 participants also reported
strong or extreme fear sometimes during the session after ad-
ministration of psilocybin at this dose (Griffiths et al. 2006,
2011). Consistent with the present findings, psilocybin also
produced significant positive effects but no negative effects
on the PE compared with the control condition, which lasted
up to 1, 2, and 14 months after the sessions (Griffiths et al.
2006, 2008, 2011). Total scores on the MS lifetime version
increased 2 months after a single dose of psilocybin (Griffiths
et al. 2006, 2008) and at the 14-month follow-up (Griffiths
et al. 2008, 2011), similar to the present findings, in whichMS
scores increased 1 and 12months after LSD administration. In
the present study, we also observed a lasting increase in scores
on the DTS Mysticism subscale, indicating an increase in
mystical experiences, which is consistent with increases in
lifetime mystical experiences on the MS, but no effects on
the other subscale. In contrast, psilocybin only slightly
changed scores on the DTS, with a slight increase on the
religious subscale but not mysticism subscale at 14 months
compared with pre-psilocybin screening (Griffiths et al.
2011).
Overall, the present study found no lasting effects of LSD
on various personality trait measures 1 or 12 months after
LSD administration. We did not confirm our study hypothesis
that LSD would increase trait openness on the NEO-FFI. In
contrast to the lack of long-term effects of LSD on personality
in the present study, NEO-PI Openness scores increased
2 weeks after administration of a lower dose of LSD (75 μg
i.v.) in healthy subjects with mostly significant prior LSD use
(Carhart-Harris et al. 2016a). These mid-term personality
changes were likely transient. Consistent with the present
LSD follow-up results, psilocybin did not alter personality
trait ratings 2 or 14 months after a single dose of psilocybin
compared with pre-psilocybin screening (Griffiths et al. 2006,
2008). Although increases in openness were noted 14 months
after psilocybin administration in a pooled analysis of both
studies (MacLean et al. 2011), another more recent study by
the same group again found no effects of psilocybin on NEO-
PI personality measures 6 months after psilocybin administra-
tion (Griffiths et al. 2017). Trait anxiety ratings on the STAI
were unchanged after LSD administration compared with pre-
LSD screening in the present study. In contrast, LSD reduced
trait anxiety ratings in patients with anxiety that was associat-
ed with life-threatening diseases (Gasser et al. 2014, 2015).
Altogether, the findings of controlled clinical studies, in-
cluding the present study (Griffiths et al. 2006, 2008, 2011,
2017; MacLean et al. 2011; McGlothlin et al. 1967), are con-
sistent with the view that serotonergic hallucinogens mainly
produce lasting increases in lifetime mystical experiences and
enduring positive effects on attitudes, mood, and behavior that
are subjectively attributed to the hallucinogen experience. In
contrast, the subjectively perceived changes did not result in
relevant long-lasting changes in personality trait measures in
healthy subjects.
The use of LSD and psilocybin has been associated with
mystical experiences (Barrett and Griffiths 2017; Lyvers and
Meester 2012). Mystical experiences that are induced by the
hallucinogen psilocybin have been shown to be associated
with long-term positive effects in healthy subjects (Griffiths
et al. 2017; MacLean et al. 2011) and therapeutic outcomes in
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patients (Garcia-Romeu et al. 2015; Griffiths et al. 2016; Ross
et al. 2016). An interesting line of investigation is to explore
the factors that contribute to these mystical experiences and
whether they specifically predict the long-term effects of hal-
lucinogens. Mystical-type experiences predicted positive ther-
apeutic outcomes in patients even after controlling for subjec-
tive intensity of the drug effect (Griffiths et al. 2016; Ross
et al. 2016). Similar to previous studies with psilocybin in
healthy subjects (Griffiths et al. 2008, 2017), the present study
found that the long-term effects of LSD were associated with
the extent of the acute response to LSD. However, the overall
alterations of mind, reflected by 5D-ASC scores, better pre-
dicted the long-term effects of LSD compared with assess-
ments of the more specific acute mystical-type experience,
such as MS acute total scores or MEQ30 scores. Thus, the
present findings indicate that the overall alterations in con-
sciousness that are acutely induced by LSD may contribute
to LSD’s lasting positive effects in normal subjects and in
patients (Gasser et al. 2015; Liechti et al. 2017).
The extent of acute hallucinogen-inducedmystical-type ex-
periences has been shown to be mainly dose-dependent
(Griffiths et al. 2011). Higher rates of meditation/spiritual
practice or greater support for spiritual practice also increased
ratings of acute mystical-type effects and contributed to the
positive long-term effects compared with a group that received
psilocybin but less spiritual support (Griffiths et al. 2017). In
this study, spiritual practice suggestions to all participants in-
cluded 10–30 min of daily meditation, awareness practice,
journaling, and other activities personally judged to facilitate
spiritual growth (Griffiths et al. 2017). However, high support
for spiritual practice included dialog group sessions to discuss
implementing and sustaining spiritual practices of meditation
and spiritual awareness and a total of 35 h of guide-participant
contact from study start to the 6-month follow-up compared
with no group sessions and only 7 h of contact in the group
with less spiritual support (Griffiths et al. 2017). Absolute
ratings of the acute mystical-type effects of the hallucinogen
on the MS and MEQ were generally higher in the studies by
Griffiths and colleagues (Barrett et al. 2015; Griffiths et al.
2006, 2008, 2011, 2017) compared with the present study
(Liechti et al. 2017). Importantly, this was the case in both
the hallucinogen and control conditions, whereas the acute
hallucinogen-induced increases in MS and MEQ scores rela-
tive to the control condition were greater after LSD than psi-
locybin administration (Barrett et al. 2015; Griffiths et al.
2006, 2011; Liechti et al. 2017). In the present study, LSD
produced mean MEQ30 ratings of 61% and a complete mys-
tical experience in only two subjects (12.5%; Liechti et al.
2017). In contrast, psilocybin produced mean MEQ30 score
ratings of 77% and a complete mystical experience in 67% of
the subjects (Barrett et al. 2015). However, placebo or active
placebo (i.e., methylphenidate) also produced MEQ30 mean
ratings of 23 and 33%, respectively, in these studies (Barrett
et al. 2015), indicating relevant differences between the stud-
ies, including research subjects characteristics (set) and setting
(Barrett and Griffiths 2017). In contrast to the studies by
Griffiths and colleagues (Griffiths et al. 2006, 2011), the par-
ticipants in the present study were mostly university students.
They received monetary compensation for participation and
were not required to be spiritually active (Liechti et al. 2017;
Schmid et al. 2015). The participants in the present study had a
personal or scientific interest in experiencing themind-altering
effects of the hallucinogen in a safe hospital environment, but
no explicit expectations or suggestions of mystical or lasting
effects were conveyed by the research team. Thus, these dif-
ferences in the study populations (spiritually active vs. not
explicitly active), preparation (suggestion of mystical/lasting
effects vs. no suggestions), and setting (esthetic living room-
like environment designed specifically for the study vs. hos-
pital ward) likely accounted for the overall lower ratings of
mystical-type effects in the present study compared with the
studies by Griffiths and colleagues (Griffiths et al. 2006,
2011). We also observed no cases of relevant mystical-type
effects after placebo administration (Liechti et al. 2017),
whereas approximately 5% of the subjects in the studies by
Griffiths and colleagues experienced a marked or total mysti-
cal experience after placebo (Barrett et al. 2015; Griffiths et al.
2011). Thus, the settings of the studies by Griffiths and col-
leagues appeared to be highly optimized to foster the emer-
gence of mystical experiences (Barrett and Griffiths 2017),
whereas fewer mystical-type experiences were reported in
studies that were conducted by other groups (Carhart-Harris
et al. 2016a; Gasser et al. 2015; Liechti et al. 2017; Studerus
et al. 2011, 2012). Notably, the effects of LSD (200 μg) in the
present study and psilocybin (30mg/70 kg) on 5D-ASC scores
were comparable (Griffiths et al. 2017; Liechti et al. 2017),
indicating similar alterations in consciousness despite the dif-
ferent settings and acute mystical experiences. Remaining to
be tested are what the high acute mystical experiences and
associated long-term effects truly reflect. High MEQ scores
(also after placebo) were observed in settings that involved
more spiritual practice/support, and these scores and associat-
ed long-term changes may partly reflect such settings
(Griffiths et al. 2017) and not the effects of psilocybin per se.
Finally, the 5D-ASC and MEQ acute effect ratings were
intercorrelated in the present study (Liechti et al. 2017). In
fact, the acute effect ratings on both the 5D-ASC and MEQ
significantly predicted long-term changes in subjective well-
being and life satisfaction on the PEQ at 12 months in the
present study. In contrast, MEQ ratings and thus specifically
the mystical-type experiences appeared to mainly predict var-
ious long-term effects of psilocybin in more spiritually active
subjects (Griffiths et al. 2008, 2017).
The present study has several limitations. First, the study
did not include a true control condition for the long-term ef-
fects of LSD (i.e., a parallel control group for the long-term
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effects and not only for the acute effects of LSD). The lasting
effects were subjectively attributed to the LSD experience
and/or compared with measures prior to the LSD session over
time and within-subjects. Thus, we cannot exclude the possi-
bility that all of these subjective effects were attributable to
expectations of positive long-term effects of LSD. Second, the
study sample was small and not sufficiently powered to detect
small effects on personality. Third, the questionnaires were
previously used in English but were mostly not validated
and the translations not validated in German. Forth, the study
was conducted in healthy subjects and used many safety pre-
cautions (Johnson et al. 2008). Therefore, the results cannot
necessarily be generalized to other settings or patients.
Negative acute responses or negative long-term effects could
occur in different populations or environments (Carbonaro
et al. 2016; Halpern et al. 2016).
In conclusion, after 1 year, a single LSD experience pro-
duced personal meaning and enhanced well-being, which
were subjectively attributed to the LSD experience, but no
relevant changes in measures of personality traits.
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